A couple of months ago, Teva Pharmaceutical Industries’ (NYSE and TASE: TEVA) chief executive Kåre Schultz indicated that he will not renew his contract as chief executive come November 2023, as the Israeli generics giant revealed plans to finalize its $4.35 billion national opioid settlement by the end of the year and start paying up in 2023, as well as reporting a loss in three out of the last four quarters.
Today, Teva announced that he would be leaving the company at the end of December this year and named a successor.
The company’s board of directors has appointed Richard Francis as president and CEO, effective January 1, 2023.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze